| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Evelo Biosciences Inc. | EDP1815 | Mild to moderate psoriasis | Phase 2 | Oral | Immunology | |
| Evelo Biosciences Inc. | EDP1815 | Atopic dermatitis | Phase 2 | Oral | Immunology | |
| Evelo Biosciences Inc. | EDP1815-205 | COVID-19 | Phase 2 | Oral | COVID-19 | |
| Evofem Biosciences Inc. | EVO100 - (EVOGUARD) | Chlamydia and gonorrhea | Phase 3 | Trial Completed | Vaginal | Antibiotic |
| Evofem Biosciences Inc. | EVO100 - (EVOGUARD) | Chlamydia and gonorrhea | Phase 3 | Trial Completed | Vaginal | Antibiotic |
| Evogene Ltd. | BMC128 with Opdivo | Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma | Phase 2 | Trial Planned | Intravenous | Oncology |
| Evogene Ltd. | BMC128 with Opdivo | Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma | Phase 2 | Trial Planned | Intravenous | Oncology |
| Evolus Inc. | Jeuveau - (extra strength) | Aesthetics | Phase 2 | Intramuscular | N/A |